BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis -related investment.

Intercept Pharmaceuticals, Inc. announced new results from a planned interim analysis of its ongoing Phase 2 study 747-213 assessing improvements in serum biomarkers of hepatic function, cholestasis and inflammation in patients with primary biliary cholangitis after treatment with an investigational combination of obeticholic acid and bezafibrate.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.

Sagimet Biosciences Inc. announced an oral presentation of data from the planned interim analysis of a prespecified subset of patients at week 26 of the Phase 2b FASCINATE-2 clinical trial of denifanstat, an investigational fatty acid synthase inhibitor, in nonalcoholic steatohepatitis patients with moderate to advanced fibrosis, stages F2 or F3, as confirmed by liver biopsy.

RELIEF THERAPEUTICS Holding SA and the World Orphan Drug Alliance announced an exclusive, long-term distribution agreement between Relief Therapeutics’ subsidiary APR Applied Pharma Research SA and WODA’s member company Vector Pharma FZCO to introduce PKU GOLIKE Plus®3-16 in the Middle East.

Molecure S.A. announces that it has filed an Investigational New Drug application with the U.S. FDA for OATD-01, a first in class and potentially disease modifying Chitotriosidase inhibitor.

Calidi Biotherapeutics, Inc. announced the commitment of $25 million in Series B funding led by Jackson Investment Group, who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi.

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced today the appointment of Ira Duarte as Chief Financial Officer.

Eli Lilly and Company announced new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 receptor agonist being studied for chronic weight management in participants with obesity or overweighti.

Sciwind Biosciences Co., Ltd. today announced that the company will present positive results from clinical studies of ecnoglutide at the 83rd American Diabetes Association (ADA) conference.